Soligenix Inc. (NASDAQ:SNGX) Sees Large Decline in Short Interest

Soligenix Inc. (NASDAQ:SNGX) was the recipient of a large decrease in short interest in the month of January. As of January 15th, there was short interest totaling 454,993 shares, a decrease of 12.5% from the December 31st total of 519,758 shares. Based on an average daily trading volume, of 182,251 shares, the short-interest ratio is currently 2.5 days. Currently, 4.7% of the company’s stock are short sold. Currently, 4.7% of the company’s stock are short sold. Based on an average daily trading volume, of 182,251 shares, the short-interest ratio is currently 2.5 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Soligenix in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $6.00.

Soligenix Stock Down 1.6%

Shares of Soligenix stock opened at $1.23 on Tuesday. Soligenix has a 52-week low of $1.09 and a 52-week high of $6.23. The company has a market capitalization of $12.41 million, a P/E ratio of -0.34 and a beta of 2.01. The company has a 50 day moving average of $1.42 and a 200 day moving average of $1.86.

Soligenix (NASDAQ:SNGX) last announced its quarterly earnings data on Friday, November 7th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.05. As a group, research analysts anticipate that Soligenix will post -4.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Banco BTG Pactual S.A. acquired a new stake in shares of Soligenix during the 3rd quarter worth about $54,000. Virtu Financial LLC purchased a new position in Soligenix in the third quarter valued at approximately $59,000. Sabby Management LLC acquired a new stake in Soligenix during the third quarter worth approximately $94,000. Two Sigma Investments LP purchased a new stake in shares of Soligenix during the 3rd quarter worth approximately $102,000. Finally, Connective Capital Management LLC lifted its position in shares of Soligenix by 17.6% during the 2nd quarter. Connective Capital Management LLC now owns 119,481 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 17,848 shares during the last quarter. 3.60% of the stock is owned by institutional investors and hedge funds.

About Soligenix

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.